We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

82 hedge funds and large institutions have $75.5M invested in Avadel Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more call options, than puts

Call options by funds: $2.87M | Put options by funds: $2.41M

15% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 20

1% more funds holding

Funds holding: 81 → 82 (+1)

7% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 15

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3.59% less ownership

Funds ownership: 60.74% → 57.15% (-3.6%)

67% less capital invested

Capital invested by funds: $230M → $75.5M (-$155M)

Holders
82
Holders Change
+1
Holders Change %
+1.23%
% of All Funds
1.38%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
16
Increased
23
Reduced
20
Closed
15
Calls
$2.87M
Puts
$2.41M
Net Calls
+$464K
Net Calls Change
-$2.46M

Top Buyers

Rank Fund Capital Flow
1
GJL
Gendell Jeffrey L
+$5.84M
2
PVI
Pura Vida Investments
New York
+$3.24M
3
BIP
Brandes Investment Partners
California
+$2.64M
4
Two Sigma Investments
Two Sigma Investments
New York
+$1.92M
5
MWM
Modera Wealth Management
New Jersey
+$1.74M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$11.4M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$9.63M
3
FLSM
Frazier Life Sciences Management
California
-$6.5M
4
ACP
Acuta Capital Partners
California
-$3.96M
5
WP
Woodline Partners
California
-$2.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$14M – – –
GJL
2
Gendell Jeffrey L
$10.4M +$5.84M +1,421,265 +50%
CAC
3
Cowen and Company
New York
$9.11M – – –
BIP
4
Brandes Investment Partners
California
$8.86M +$2.64M +642,800 +22%
VC
5
Vivo Capital
California
$7.17M – – –
WE
6
Wealth Effects
Massachusetts
$6.3M +$849K +206,800 +9%
WP
7
Woodline Partners
California
$3.87M -$2.18M -530,737 -25%
Renaissance Technologies
8
Renaissance Technologies
New York
$2.08M +$409K +99,700 +13%
PVI
9
Pura Vida Investments
New York
$1.93M +$3.24M +789,181 New
SB
10
Samsara BioCapital
California
$1.61M – – –
Two Sigma Investments
11
Two Sigma Investments
New York
$1.14M +$1.92M +468,559 New
MWM
12
Modera Wealth Management
New Jersey
$1.03M +$1.74M +423,000 New
MB
13
MPM BioImpact
Massachusetts
$1.01M – – –
Morgan Stanley
14
Morgan Stanley
New York
$772K -$109K -26,648 -8%
DMKJ
15
David M. Knott Jr
$546K +$66.2K +16,117 +8%
Millennium Management
16
Millennium Management
New York
$519K +$873K +212,590 New
State Street
17
State Street
Massachusetts
$420K -$139K -33,842 -16%
CIBC Private Wealth Group
18
CIBC Private Wealth Group
Georgia
$403K +$242K +58,934 +56%
Citadel Advisors
19
Citadel Advisors
Florida
$393K +$305K +74,365 +86%
EWM
20
Edge Wealth Management
New York
$381K +$45.2K +11,000 +8%
Lazard Asset Management
21
Lazard Asset Management
New York
$347K -$14.6K -3,565 -2%
IAMOG
22
Investors Asset Management of Georgia
Georgia
$341K +$191K +46,500 +50%
Deutsche Bank
23
Deutsche Bank
Germany
$305K -$897K -218,407 -64%
Ameriprise
24
Ameriprise
Minnesota
$273K -$69.7K -16,968 -13%
SC
25
Schulhoff & Co
Ohio
$234K +$144K +35,000 +57%
1
2 3 4

AVDL Hedge Fund Activity: Q2 2022 in Review

82 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2022, worth a combined $75.5M — down 67% from $230M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new AVDL positions and 15 closed out — a net gain of 1 holder — while 23 added to existing stakes and 20 trimmed.

The largest buyer was Gendell Jeffrey L, adding an estimated $5.84M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $11.4M sold.

  • 82 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2022, up from 81 in Q1 2022.
  • Funds reported $75.5M of Avadel Pharmaceuticals stock for Q2 2022, down 67% quarter-over-quarter.
  • 16 funds opened new Avadel Pharmaceuticals positions in Q2 2022 and 15 closed out, a net change of +1 holder.
  • The largest Avadel Pharmaceuticals buyer in Q2 2022 was Gendell Jeffrey L, an estimated $5.84M added.
  • The largest Avadel Pharmaceuticals seller in Q2 2022 was Avoro Capital Advisors, an estimated $11.4M sold.

Based on aggregated 13F filings for Q2 2022.